Marc Hedrick | President & CEO |
Norman LaFrance | Chief Medical Officer |
Andrew Sims | CFO |
Jianing Li | Maxim Group |
Sean Lee | H.C. Wainwright |
Ed Woo | Ascendiant Capital |
Good afternoon, ladies and gentlemen, and welcome to the Plus Therapeutics Fourth Quarter and Full Year 2021 Results Call. At this time, all participants have been placed in a listen-only mode, and the floor will be open for your questions following the presentation. [Operator Instructions].
Before we begin, we want to advice you that over the course of the call and question-and-answer session, forward-looking statements will be made regarding events, trends, business prospects and financial performance, which may affect Plus Therapeutics' future operating results and financial position. All such statements are subject to risks and uncertainties and including the risks and uncertainties described under the Risk Factors section included in Plus Therapeutics' annual reports on Form 10-K and quarterly reports on Form 10-Q filed with the Securities and Exchange Commission from time to time.